Contradictory findings regarding the safety and efficacy of the dual-nucleoside combination of abacavir and 3TC were presented in a late-breaker session at the XVII International AIDS Conference. A secondary analysis of 48-week data from the ACTG5202 study reasserted that the dual-nucleoside backbone of abacavir plus 3TC was more likely to lead to toxicity and earlier virologic failure than tenofovir plus FTC. However, a presentation from GlaxoSmithKline (GSK) indicated that, when data from other well-designed clinical trials was analysed using the same study endpoints as ACTG5202, abacavir/3TC proved just as tolerable and effective as tenofovir/FTC. http://www.aidsmap.org/en/news/6A8BAFF8-1486-4553-812A-E2F9763B886B.asp
See also article from March 2008 issue of Positive Living